Bluejay Diagnostics, Inc. (BJDX) Stock Score, Valuation & Financial Research

Bluejay Diagnostics, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BJDX

Bluejay Diagnostics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.85. These figures are a research snapshot, not a buy or sell recommendation.

What Bluejay Diagnostics, Inc. does

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Bluejay Diagnostics is a medical diagnostics company currently in the development stage. It does not yet generate revenue from product sales, as its primary product candidate, the Symphony System, has not received regulatory clearance from the U.S. Food and Drug Administration. The company currently funds its operations primarily through equity financing, including private placements and public offerings.

Products and services

  • The company is developing the Symphony System, a rapid, near-patient diagnostic platform designed for sepsis triage and monitoring disease progression, featuring an IL-6 test candidate.

Brands and product families

  • Symphony System — The company's primary diagnostic platform candidate currently under development. Source

Customer types

Hospitals; Clinical Laboratories.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its diagnostic systems and test cartridges; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Established diagnostic companies — The company competes with various established diagnostic companies that offer rapid testing solutions for sepsis and other critical care conditions. Source

Business strengths to evaluate

  • Development of a rapid, near-patient diagnostic platform for sepsis triage Source

Business risks and research considerations

  • Lack of regulatory clearance for the Symphony System Source
  • History of operating losses and dependence on external financing Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BJDX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.85
Market capitalization:
884.58K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -7.27M
Free cash flow:
USD -6.23M
Cash:
USD 9.6M
Total debt:
USD 80.67K
EPS:
USD -11.80

What stands out

  • Free cash flow is USD -6.23M, negative for the stored period.
  • The balance sheet shows USD 9.6M of cash versus USD 80.67K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 9.52M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BJDX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BJDX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BJDX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BJDX to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BJDX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BJDX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.